Atea Pharmaceuticals, Inc. Tax Withholding Paid on Stock Awards
Atea Pharmaceuticals, Inc. (AVIR) reported Tax Withholding Paid on Stock Awards of $746.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2026-08-12
- Atea Pharmaceuticals, Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2026-06-30 was $0.00.
- Atea Pharmaceuticals, Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2026-03-31 was $746.00K, a 53.81% increase year-over-year.
- Atea Pharmaceuticals, Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2025-12-31 was $0.00.
- Atea Pharmaceuticals, Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2025-09-30 was $0.00.
- Atea Pharmaceuticals, Inc. payment, tax withholding, share-based payment arrangement for fiscal 2025 was $485.00K.
- Atea Pharmaceuticals, Inc. payment, tax withholding, share-based payment arrangement for fiscal 2024 was $0.00.
| Period end | Payment, Tax Withholding, Share-based Payment Arrangement 3 month | Payment, Tax Withholding, Share-based Payment Arrangement 6 month | Payment, Tax Withholding, Share-based Payment Arrangement 9 month | Payment, Tax Withholding, Share-based Payment Arrangement 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $746.00K 10-Q · filed 2026-08-12 | $746.00K derived: sum of 3 quarters · filed 2026-08-12 | $746.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $746.00K 10-Q · filed 2026-05-12 | $746.00K derived: sum of 2 quarters · filed 2026-05-12 | $746.00K derived: sum of 3 quarters · filed 2026-05-12 | $746.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $0.00 derived: sum of 2 quarters · filed 2026-03-05 | $0.00 derived: sum of 3 quarters · filed 2026-08-12 | $485.00K 10-K · filed 2026-03-05 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $0.00 derived: sum of 2 quarters · filed 2026-08-12 | $485.00K 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $485.00K 10-Q · filed 2026-08-12 | ||
| 2025-03-31 | $485.00K 10-Q · filed 2026-05-12 | |||
| 2024-12-31 | $0.00 10-K · filed 2026-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |